Good morning, you're listening to Markets Desk.
A late-stage clinical trial for pancreatic cancer has stunned the oncology world, with a new treatment nearly doubling patient survival rates. The announcement drew a standing ovation from doctors and researchers at a major global conference on Sunday, a rare and telling reaction from a typically reserved scientific audience. Pancreatic cancer has historically been among the most lethal diagnoses, and results of this magnitude carry serious implications for the biotech and pharmaceutical sectors watching the space closely.
Shifting to venture capital, Chinese AI startup VAST has reached unicorn status after closing two hundred million dollars in fresh funding. Founded by Forbes thirty Under thirty Asia honoree Simon Song, the company builds three-dimensional modeling tools powered by artificial intelligence. The raise reflects continued investor appetite for AI infrastructure plays, particularly those targeting visual and spatial computing, even as broader tech valuations remain under scrutiny.
And in Hollywood, the studios are no longer fighting artificial intelligence — they're racing to own it. Amazon, Lionsgate, Netflix, and SAG-AFTRA are actively reshaping the contractual and creative rules around AI in film production. The pivot from resistance to control signals that the industry sees AI not as a threat to manage but as a competitive lever to capture, and the capital flowing into that bet is accelerating.
That's the tape. Markets Desk, signing off the floor.
